MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock-Private...
$120,000K
Proceeds from royalty
obligation
$75,000K
Proceeds from issuance of
common stock-At Market...
$28,573K
Proceeds from exercise of
stock options
$4,096K
Proceeds from issuance of
common stock under...
$276K
Net cash provided by
financing activities
$215,280K
Canceled cashflow
$12,665K
Net (decrease)
increase in cash, cash...
-$209,191K
Canceled cashflow
$215,280K
Proceeds from sales and
maturities of investments
$200,887K
Acquired in-process
research and development
$171,672K
Stock-based compensation
expense
$26,347K
Accrued expenses
$15,052K
Non-cash interest
expense on royalty...
$7,327K
Non-cash lease expense
$875K
Loss on disposal of
property and equipment
-$107K
Depreciation expense
$56K
Payment of agent fees and
offering costs-Private...
$12,665K
Net cash used in
investing activities
-$251,886K
Canceled cashflow
$200,887K
Net cash used in
operating activities
-$172,333K
Effect of exchange rate
changes on cash, cash...
-$252K
Canceled cashflow
$221,436K
Purchases of investments
$417,755K
Product candidate
license acquisitions
$35,000K
Purchases of property and
equipment
$18K
Net loss
-$377,737K
Accounts payable
-$10,043K
Prepaid expenses and
other assets
$3,156K
Net amortization of
premiums and accretion of...
-$1,931K
Operating lease
liabilities
-$902K
Back
Back
Cash Flow
source: myfinsight.com
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)